A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Phase 3

Recruiting

• Conditions: Essential Thrombocythemia
• Interventions: Drug: Anagrelide; Drug: Bomedemstat; Drug: Busulfan; Drug: Interferon alfa/pegylated interferon alfa; Drug: Ruxolitinib

• Registration Number: NCT06079879
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This is a study evaluating the safety and efficacy of bomedemstat (MK-3543) compared with the best available therapy (BAT) in participants with essential thrombocythemia (ET) who have an inadequate response to or are intolerant of hydroxyurea.
...

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2023-10-06
• Study First Submitted QC: 2023-10-06
• Study First Posted: 2023-10-12
• Study Start: 2023-12-31
• Status Verified: 2024-12
• Last Update Submitted: 2024-12-05
• Last Update Posted: 2024-12-06
• Primary Completion: 2026-08-18
• Study Completion: 2028-08-18

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Has a diagnosis of ET per WHO 2016 diagnostic criteria for myeloproliferative neoplasms
• Has a bone marrow fibrosis score of Grade 0 or Grade 1, as per a modified version of the European Consensus Criteria for Grading Myelofibrosis
• Has a history of inadequate response to or intolerance of hydroxyurea based on modified European LeukemiaNet (ELN) criteria for hydroxyurea resistance or intolerance: hydroxyurea resistance (or inadequate response) or hydroxyurea Intolerance
• Has an inadequate or loss of response to their most recent prior ET therapy, requiring a change of cytoreductive therapy
• Has a platelet count > 450 × 10^9/L (450k /μL) assessed up to 72 hours before first dose of study intervention
• Has an absolute neutrophil count (ANC) ≥0.75 × 10^9/L assessed up to 72 hours before first dose of study intervention
• Participants may have received up to 3 prior lines of therapy including hydroxyurea

Read More

Exclusion Criteria

• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to bomedemstat or lysine demethylase or monoamine oxidase inhibitor (LSDi or MAOi) or the chosen best available therapy (including anagrelide, interferon alfa/pegylated interferon, ruxolitinib, or busulfan) that contraindicates participation
• History of any illness/impairment of GI function that might interfere with drug absorption (eg, chronic diarrhea or history of gastric bypass surgical procedure), confound the study results or pose an additional risk to the individual by participation in the study
• Evidence at the time of Screening of increased risk of bleeding
• History of a malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years. Note: The time requirement does not apply to participants who underwent successful definitive resection of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ, excluding carcinoma in situ of the bladder
• Human immunodeficiency virus (HIV)-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Best Available Therapy	Anagrelide	Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 152 weeks at the investigators discretion.
Best Available Therapy	Interferon alfa/pegylated interferon alfa	Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 152 weeks at the investigators discretion.
Best Available Therapy	Busulfan	Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 152 weeks at the investigators discretion.
Bomedemstat	Bomedemstat	Participants will begin treatment at a dose of 50 mg of bomedemstat daily. Dosage will be adjusted either up or down within specified time parameters for each participant to the dose that provides sufficient exposure to safely inhibit thrombopoiesis to decrease platelet counts to the target range. All participants will be treated daily for up to 52 weeks, and are eligible for an extended treatment phase up to 152 weeks.
Best Available Therapy	Ruxolitinib	Each participant will receive either anagrelide, busulfan, interferon alfa/pegylated interferon alfa, or ruxolitinib as determined by investigator. All participants will be treated per respective approved product labels for up to 52 weeks. Participants receiving BAT for 52 weeks who stop responding to BAT are eligible to switch to bomedemstat and receive this for up to 152 weeks at the investigators discretion.

Primary Outcome Measures

Name	Time	Method
Durable Clinicohematologic Response (DCHR) Rate	Up to approximately 52 weeks	DCHR rate is the percentage of participants with DCHR, defined as a confirmed reduction of platelet count to ≤400 × 10\^9/L, absence of white blood cell (WBC) count elevation to \>10 × 10\^9/L locally assessed to be due to ET, and the absence of any thrombotic or major hemorrhagic events or disease progression to myelofibrosis (MF), myelodysplastic syndrome ...

Secondary Outcome Measures

Name	Time	Method
Event Free Survival (EFS)	Up to approximately 52 weeks	Event free survival (EFS) is defined as the time from randomization to the first documented thrombotic or major hemorrhagic event or disease progression as assessed by the adjudication committee, or death due to any cause, whichever occurs first.
Change From Baseline in Patient-reported Outcomes Measurement Information System (PROMIS) Fatigue SF-7a Total Fatigue Score	Baseline and pre-specified timepoints through Week 156	The PROMIS F SF-7a is a 7-item participant-reported assessment that measures both the experience of fatigue and the interference of fatigue on daily activities over the past week. Response options are on a 5-point Likert scale, ranging from 1 = never to 5 = always. Change from baseline in PROMIS Fatigue SF-7a through Week 156 will be presented.
Percentage of Participants with Major Hemorrhagic Events	Up to 156 weeks	Major hemorrhagic events include but are not limited to fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a decrease in hemoglobin level of 2 g/dL or more, or leading to tra...
Duration of Clinicohematologic Response (DOCHR)	Up to approximately 52 weeks	For participants who demonstrate DCHR, duration of clinicohematologic response is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC count until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events or disease progression to MF, MDS or AML.
Percentage of Participants with Thrombotic Events	Up to 156 weeks	Thrombotic events include but are not limited to new or recurrent acute myocardial infarction, unstable angina, stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, thrombotic digital ischemia, or other thrombotic events.
Change From Baseline in Myelofibrosis Symptom Assessment Form (MFSAF) v4.0 Individual Fatigue Symptom Item Score	Baseline and pre-specified timepoints through Week 156	The MFSAF v4.0 is a 7-item participant-reported myelofibrosis symptom assessment which asks respondents to report symptom severity at its worst for each of the 7 items on a 0 (Absent) to 10 (Worst Imaginable) numeric rating scale. For this outcome measure, the change from baseline through Week 156 in scores for the individual item of fatigue severity will be...
Change From Baseline in Total Symptom Score as Measured on the MFSAF v4.0	Baseline and pre-specified timepoints through Week 156	The MFSAF v4.0 is a 7-item participant-reported myelofibrosis symptom assessment which asks respondents to report symptom severity at its worst for each of the 7 items on a 0 (Absent) to 10 (Worst Imaginable) numeric rating scale. MFSAF total score for all symptoms at baseline through Week 156 will be presented.
Duration of Hematologic Remission (DOHR)	Up to approximately 52 weeks	For participants who demonstrate hematologic remission, DOHR is defined as the time from the first documented evidence of platelet and WBC counts reduction until platelet or WBC counts increase to above acceptable threshold.
Number of Participants with An Adverse Event (AE)	Up to 180 weeks	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Disease Progression Rate	Up to approximately 52 weeks	Disease progression rate is the percentage of participants with disease progression, defined as the transformation to post-essential thrombocythemia myelofibrosis, myelodysplastic syndrome, or acute myeloid leukemia as assessed by the adjudication committee. The disease progression rate of participants in each arm will be presented.
Number of Participants Discontinuing From Study Therapy Due to an AE	Up to 152 weeks	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an adverse event will be presented.

Trial Locations

Locations (133)

Anhui Provincial Hospital ( Site 3513); 🇨🇳 Hefei, Anhui, China

Peking University Third Hospital-Hematology ( Site 3502); 🇨🇳 Beijing, Beijing, China

The Second Affiliated Hospital Of Fujian Medical University ( Site 3525); 🇨🇳 Quanzhou, Fujian, China

Sun Yat-sen Memorial Hospital of Sun Yat-sen University ( Site 3524); 🇨🇳 Guangzhou, Guangdong, China

Southern Medical University Nanfang Hospital-Department of Hematopathology ( Site 3511); 🇨🇳 Guangzhou, Guangdong, China

The First Hospital of Hebei Medical University ( Site 3510); 🇨🇳 Shijiazhuang, Hebei, China

Henan Cancer Hospital-hematology department ( Site 3504); 🇨🇳 Zhengzhou, Henan, China

Wuhan Union Hospital ( Site 3500); 🇨🇳 Wuhan, Hubei, China

Affiliated Hospital of Nantong University ( Site 3527); 🇨🇳 Nantong, Jiangsu, China

The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3505); 🇨🇳 Nanchang, Jiangxi, China

The First Hospital of Jilin University-Hematology ( Site 3526); 🇨🇳 Changchun, Jilin, China

Shaanxi provincial people's hospital ( Site 3516); 🇨🇳 Xian, Shaanxi, China

Jinan Central Hospital ( Site 3523); 🇨🇳 Jinan, Shandong, China

Huashan Hospital, Fudan University ( Site 3529); 🇨🇳 Shanghai, Shanghai, China

West China Hospital, Sichuan University ( Site 3518); 🇨🇳 Cheng Du, Sichuan, China

Institute of hematology&blood disease hospital ( Site 3501); 🇨🇳 Tianjin, Tianjin, China

The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3508); 🇨🇳 Hangzhou, Zhejiang, China

Zhejiang University School of Medicine-The Fourth Affiliated Hospital ( Site 3517); 🇨🇳 Yiwu, Zhejiang, China

Fundacion Colombiana de Cancerología Clinica Vida ( Site 1403); 🇨🇴 Medellin, Antioquia, Colombia

Oncomedica S.A.S ( Site 1401); 🇨🇴 Montería, Cordoba, Colombia

Los Cobos Medical Center ( Site 1404); 🇨🇴 Bogota, Distrito Capital De Bogota, Colombia

Hôpital Saint Antoine-Service d'Hématologie et de Thérapie Cellulaire ( Site 1702); 🇫🇷 Paris, Ile-de-France, France

Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 0417); 🇫🇷 Rennes, Ille-et-Vilaine, France

Centre Hospitalier Régional Universitaire de Tours - Hôpital-Hématologie et Thérapie Cellulaire ( Si; 🇫🇷 Tours, Indre-et-Loire, France

Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois-HEMATOLOGY ( Site 0407); 🇫🇷 Vandoeuvre lès Nancy, Lorraine, France

centre hospitalier lyon sud ( Site 0406); 🇫🇷 Pierre-Bénite, Rhone, France

Hôpital Saint-Louis-Centre d'Investigations Cliniques ( Site 0405); 🇫🇷 Paris, France

Universitätsklinikum Aachen ( Site 1801); 🇩🇪 Aachen, Nordrhein-Westfalen, Germany

Universitätsklinikum Halle ( Site 0401); 🇩🇪 Halle, Sachsen-Anhalt, Germany

Universitaetsklinikum Carl Gustav Carus Dresden-Medical Dept I - Medical Oncology ( Site 0402); 🇩🇪 Dresden, Sachsen, Germany

Queen Mary Hospital ( Site 1901); 🇭🇰 Hksar, Hong Kong

Petz Aladar Egyetemi Oktato Korhaz ( Site 2000); 🇭🇺 Győr, Gyor-Moson-Sopron, Hungary

Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókór-Haematológia osztály ( Site 0706); 🇭🇺 Nyiregyhaza, Szabolcs-Szatmar-Bereg, Hungary

Semmelweis Egyetem-Belgyógyászati és Hematológiai Klinika ( Site 0708); 🇭🇺 Budapest, Hungary

Debreceni Egyetem Klinikai Kozpont-Belgyógyászati Klinika (Haematologia) ( Site 0707); 🇭🇺 Debrecen, Hungary

Rambam Health Care Campus ( Site 2102); 🇮🇱 Haifa, Israel

Hadassah Medical Center ( Site 0904); 🇮🇱 Jerusalem, Israel

Sheba Medical Center ( Site 2101); 🇮🇱 Ramat Gan, Israel

Sourasky Medical Center ( Site 0902); 🇮🇱 Tel Aviv, Israel

Yitzhak Shamir Medical Center. ( Site 0901); 🇮🇱 Zerifin, Israel

Azienda Ospedaliero Universitaria di Ferrara ( Site 0304); 🇮🇹 Cona, Ferrara, Italy

Fukushima Medical University ( Site 3616); 🇯🇵 Fukushima, Japan

University of Miyazaki Hospital ( Site 3609); 🇯🇵 Miyazaki, Japan

Okayama University Hospital ( Site 3604); 🇯🇵 Okayama, Japan

Hospital Universitario 12 de Octubre ( Site 2806); 🇪🇸 Madrid, Spain

Hospital Universitario Virgen de la Victoria ( Site 0418); 🇪🇸 Malaga, Spain

Kyushu University Hospital ( Site 3605); 🇯🇵 Fukuoka, Japan

Centre Hospitalier de Roubaix ( Site 1703); 🇫🇷 Roubaix, Nord, France

Tufts Medical Center ( Site 3408); 🇺🇸 Boston, Massachusetts, United States

University of Michigan ( Site 0008); 🇺🇸 Ann Arbor, Michigan, United States

Henry Ford Hospital ( Site 3413); 🇺🇸 Detroit, Michigan, United States

Duke University Health System (DUHS) ( Site 0016); 🇺🇸 Durham, North Carolina, United States

Wake Forest Baptist Health-Internal Medicine, Section on Hematology & Oncology ( Site 3400); 🇺🇸 Winston-Salem, North Carolina, United States

VCU Health Adult Outpatient Pavillion ( Site 3416); 🇺🇸 Richmond, Virginia, United States

Hospital Universitario Austral ( Site 0104); 🇦🇷 Pilar, Buenos Aires, Argentina

Hospital Italiano de Buenos Aires ( Site 0105); 🇦🇷 ABB, Caba, Argentina

C.I.C.E. 9 de Julio ( Site 1001); 🇦🇷 San Miguel de Tucumán, Tucuman, Argentina

Royal Prince Alfred Hospital ( Site 1100); 🇦🇺 Camperdown, New South Wales, Australia

Liverpool Hospital-Haematology ( Site 0501); 🇦🇺 Liverpool, New South Wales, Australia

Royal North Shore Hospital ( Site 0003); 🇦🇺 St Leonards, New South Wales, Australia

Calvary Mater Newcastle ( Site 0505); 🇦🇺 Waratah, New South Wales, Australia

Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 0001); 🇦🇺 Adelaide, South Australia, Australia

Monash Health-Haematology Research ( Site 0006); 🇦🇺 Clayton, Victoria, Australia

Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 0502); 🇦🇺 Melbourne, Victoria, Australia

Royal Perth Hospital-Haematology ( Site 0504); 🇦🇺 Perth, Western Australia, Australia

The Moncton Hospital-Oncology ( Site 1500); 🇨🇦 Moncton, New Brunswick, Canada

The First Afflilated Hospital of Bengbu Medical College ( Site 3509); 🇨🇳 Bengbu, Anhui, China

IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0308); 🇮🇹 Meldola, Forli-Cesena, Italy

Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 2201); 🇮🇹 Milano, Lombardia, Italy

Azienda Ospedaliera Universitaria Careggi ( Site 0030); 🇮🇹 Firenze, Toscana, Italy

Azienda Ospedaliero Universitaria Pisana-UO Ematologia UNIV ( Site 0309); 🇮🇹 Pisa, Toscana, Italy

Istituto Oncologico Veneto IRCCS-Oncoematologia ( Site 0306); 🇮🇹 Castelfranco Veneto, Veneto, Italy

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo ( Site 0034); 🇮🇹 Alessandria, Italy

Azienda Ospedaliero Universitaria delle Marche ( Site 0302); 🇮🇹 Ancona, Italy

Arcispedale Santa Maria Nuova ( Site 0301); 🇮🇹 Reggio Emilia, Italy

Ospedale Mauriziano ( Site 0305); 🇮🇹 Torino, Italy

Ospedale di Circolo e Fondazione Macchi Varese ( Site 2200); 🇮🇹 Varese, Italy

Fujita Health University ( Site 3613); 🇯🇵 Toyoake, Aichi, Japan

National Cancer Center Hospital East ( Site 3610); 🇯🇵 Kashiwa, Chiba, Japan

Ehime University Hospital ( Site 3612); 🇯🇵 Toon, Ehime, Japan

Hokkaido University Hospital ( Site 3601); 🇯🇵 Sapporo, Hokkaido, Japan

Kobe City Medical Center General Hospital ( Site 3603); 🇯🇵 Kobe, Hyogo, Japan

Kanazawa University Hospital ( Site 3614); 🇯🇵 Kanazawa, Ishikawa, Japan

Mie University Hospital ( Site 3615); 🇯🇵 Tsu, Mie, Japan

National Hospital Organization Sendai Medical Center ( Site 3617); 🇯🇵 Sendai, Miyagi, Japan

Kansai Medical University Hospital ( Site 3607); 🇯🇵 Hirakata, Osaka, Japan

Kindai University Hospital- Osakasayama Campus-Hematology and Rheumatology ( Site 3600); 🇯🇵 Osakasayama, Osaka, Japan

Juntendo University Hospital ( Site 3611); 🇯🇵 Bunkyo-ku, Tokyo, Japan

Nippon Medical School Hospital ( Site 3608); 🇯🇵 Bunkyo-ku, Tokyo, Japan

University of Yamanashi Hospital ( Site 3606); 🇯🇵 Chuo, Yamanashi, Japan

Seoul National University Bundang Hospital-Hematology ( Site 0605); 🇰🇷 Seongnam, Kyonggi-do, Korea, Republic of

Korea University Anam Hospital ( Site 0604); 🇰🇷 Seoul, Korea, Republic of

Asan Medical Center ( Site 0603); 🇰🇷 Seoul, Korea, Republic of

The Catholic Univ. of Korea Seoul St. Mary's Hospital ( Site 0606); 🇰🇷 Seoul, Korea, Republic of

Spaarne Gasthuis - Hoofddorp-Oncology ( Site 2301); 🇳🇱 Hoofddorp, Noord-Holland, Netherlands

Albert Schweitzer Ziekenhuis, locatie Dordwijk-Internal Medicine ( Site 2302); 🇳🇱 Dordrecht, Zuid-Holland, Netherlands

Martini Ziekenhuis ( Site 2300); 🇳🇱 Groningen, Netherlands

North Shore Hospital-Department of Haematology ( Site 0051); 🇳🇿 Auckland, New Zealand

Aotearoa Clinical Trials ( Site 0050); 🇳🇿 Auckland, New Zealand

Pratia Onkologia Katowice ( Site 0702); 🇵🇱 Katowice, Slaskie, Poland

Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Hematologii i Transplantacji S; 🇵🇱 Kielce, Swietokrzyskie, Poland

Unidade Local de Saude de Braga - Hospital de Braga ( Site 0415); 🇵🇹 Braga, Portugal

Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 2600); 🇵🇹 Lisboa, Portugal

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 0414); 🇵🇹 Porto, Portugal

Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 0409); 🇪🇸 Badalona, Barcelona, Spain

Institut Català d'Oncologia - L'Hospitalet-Haematology Department ( Site 2801); 🇪🇸 L'Hospitalet Del Llobregat, Barcelona, Spain

HOSPITAL CLÍNIC DE BARCELONA ( Site 2800); 🇪🇸 Barcelona, Cataluna, Spain

CHUS - Hospital Clinico Universitario ( Site 0421); 🇪🇸 Santiago de Compostela, La Coruna, Spain

Hospital Universitario Ramón y Cajal-Hematology ( Site 2803); 🇪🇸 Madrid, Madrid, Comunidad De, Spain

Hospital Costa del Sol-Hematology Service ( Site 0412); 🇪🇸 Marbella, Malaga, Spain

Hospital General Universitario de Albacete ( Site 0408); 🇪🇸 Albacete, Spain

Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0404); 🇪🇸 Barcelona, Spain

Hospital Universitario de Salamanca - Complejo Asistencial U-Servicio de Hematologia ( Site 0419); 🇪🇸 Salamanca, Spain

Hospital Universitario Doctor Peset ( Site 0411); 🇪🇸 Valencia, Spain

Universitetssjukhuset Örebro ( Site 0403); 🇸🇪 Örebro, Orebro Lan, Sweden

Karolinska Universitetssjukhuset Huddinge ( Site 2900); 🇸🇪 Huddinge, Stockholms Lan, Sweden

Chang Gung Memorial Hospital- Chiayi ( Site 3102); 🇨🇳 Chiayi City, Chiayi, Taiwan

Chang Gung Memorial Hospital at Kaohsiung-Division of Hematology and Oncology ( Site 3104); 🇨🇳 Kaohsiung, Taiwan

National Cheng Kung University Hospital-Clinical Trial Center ( Site 3105); 🇨🇳 Tainan, Taiwan

National Taiwan University Hospital ( Site 3101); 🇨🇳 Taipei, Taiwan

Chang Gung Medical Foundation-Linkou Branch ( Site 3103); 🇨🇳 Taoyuan, Taiwan

Hacettepe Universite Hastaneleri-Department of Hematology ( Site 3204); 🇹🇷 Ankara, Turkey

Ankara Bilkent Şehir Hastanesi ( Site 3201); 🇹🇷 Ankara, Turkey

Antalya Egitim ve Arastırma Hastanesi ( Site 3207); 🇹🇷 Antalya, Turkey

Trakya University Medical Faculty Hospital-Hematology ( Site 3200); 🇹🇷 Edirne, Turkey

Medipol Mega Universite Hastanesi-oncology ( Site 3203); 🇹🇷 Istanbul, Turkey

Kocaeli Üniversitesi-Hematology ( Site 3205); 🇹🇷 Kocaeli, Turkey

Ondokuz Mayıs Universitesi-hematology ( Site 3206); 🇹🇷 Samsun, Turkey

Addenbrooke's Hospital ( Site 3303); 🇬🇧 Cambridge, Cambridgeshire, United Kingdom

Lincoln County Hospital ( Site 3310); 🇬🇧 Lincoln, Great Britain, United Kingdom

Boston Pilgrim Hospital ( Site 3301); 🇬🇧 Boston, Lincolnshire, United Kingdom

Royal Gwent Hospital ( Site 3304); 🇬🇧 Gwent, Newport, United Kingdom

The Christie NHS Foundation Trust ( Site 3307); 🇬🇧 Manchester, United Kingdom